Genetically modified T cells target lymphoma

From Nature Outlook, 14 November 2018: First-in-human trials are risky. That’s why they tend to involve the sickest of the sick — people whose disease has progressed beyond the reach of any existing treatment, and who have no other options. So it is a testament to the revolutionary nature of chimeric antigen receptor T-cell therapy Continue reading Genetically modified T cells target lymphoma